Login to Your Account

Amgen buoyed on Repatha cardiovascular data, positive fourth-quarter earnings

By Michael Fitzhugh
Staff Writer

Friday, February 3, 2017

Estimate-beating fourth-quarter earnings for Amgen Inc. pushed company shares about $7.95 higher to close at $167.53 on Friday as sales of its cholesterol treatment Repatha rose.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription